Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-GRR2 trial of allogeneic mesenchymal stromal cells for steroid- and ruxolitinib-refractory acute graft-versus-host disease
2025-523448-10-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stromal cells, ex vivo cultured in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Overall response rate at day 28. Planned start Sep 2026; status: authorised.
02
Drugs
mesenchymal stromal cells, ex vivo cultured
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2025-523448-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523448-10-00.